Department of Rehabilitation, C.R.R.F. "Mons. L. Novarese", Loc. Trompone, Moncrivello, Italy.
Department of Neurology and Regional Referral Multiple Sclerosis Centre, University-Hospital S. Luigi Gonzaga, Orbassano, Italy.
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19.
髓鞘少突胶质细胞糖蛋白抗体病（MOGAD）是一种脱髓鞘疾病，已尝试用托珠单抗（一种抗白细胞介素 6 受体的药物）来预防致残性复发。在受新型冠状病毒病（COVID-19）影响的患者亚组中，托珠单抗也提高了生存率。我们报告了一例 31 岁白人患者的病例，该患者在接受托珠单抗治疗期间感染了几乎无症状的严重急性呼吸综合征冠状病毒（SARS-CoV-2），但由于患者复发的极高风险，托珠单抗治疗仍在继续。根据该病例，COVID-19 期间可能不应停用托珠单抗。
